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Background: Patients with type 2 diabetes mellitus (T2DM) have reduced P2Y12 inhibitory effects compared to non-diabetics following treatment 
with standard clopidogrel maintenance dosing. High clopidogrel maintenance dosing and adjunctive cilostazol therapy (“triple therapy”) have both 
shown to enhance P2Y12 inhibition in T2DM patients. However, which of these options is more effective in enhancing P2Y12 inhibitory effects in 
T2DM patients with suboptimal response to standard clopidogrel dosing is unknown. The aim of this study was to compare the functional impact of 
adjunctive cilostazol therapy versus high clopidogrel maintenance dosing in T2DM patients with suboptimal clopidogrel response.
Methods: T2DM patients with coronary artery disease on clopidogrel (75 mg/day) for at least one-month were screened to identify suboptimal 
responders. All patients were on aspirin (81mg/day). A P2Y12 reactivity index (PRI), determined by assessment of phosphorylated status of 
vasodilator phosphoprotein, greater than 50% identified patients as suboptimal responders. A total of 30 patients with suboptimal clopidogrel 
response were studied. Patients received cilostazol 100 mg twice daily for 14 days in addition to aspirin and clopidogrel (n=15) or high dose 
clopidogrel (150 mg) for 30 days (n=15). Platelet function was performed at baseline and after the treatment period.
Results: There were no differences in baseline characteristics among groups. PRI values prior to treatment assignment were similar between 
groups (67.5±8.5 vs. 70.7±14.6; p=0.477). After treatment, patients assigned to cilostazol therapy had lower PRI than those treated with 150 mg 
clopidogrel (45.1±16.2 vs. 57.5±14.7; p=0.038). The absolute change in PRI was 22.4±12.2 for the cilostazol group and 13.2±11.8 for the high 
dose clopidogrel group (p=0.045), leading to a 9.2% (confidence interval 95%: 2.2% - 18.2%) greater decrease in PRI associated with cilostazol.
Conclusions: In T2DM patients with suboptimal clopidogrel response while on a standard dual antiplatelet regimen, adjunctive treatment with 
cilostazol is associated with greater P2Y12 inhibitory effects compared to high clopidogrel maintenance dosing.
